A Phase 3 interventional study of Dupilumab SAR231893 and Placebo in Chronic Spontaneous Urticaria, sponsored by Sanofi. Completed at 98 sites in 11 countries. Open to participants aged 6 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-20.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.
Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 13th largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2019, is one of 21 in phase 3, and was the 26th registered.
197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.
Browse Chronic Urticaria studies →9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:
Calixis Inc. · Sites in United States
Ages 18–85
Enanta Pharmaceuticals, Inc · Sites in United States
Ages 18–65 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 6 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 25 · Phase 3 22 · Phase 4 4
First in 2008; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 397 is above the median of 80 across 147 interventional studies indexed under Chronic Urticaria.
Median enrollment 132 across the 58 interventional studies, 428 across the 6 observational. Of the 44 that completed or were terminated, 30 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 64 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 5 studies filed under Chronic Urticaria — fewer than ten, so there is no comparison to draw.
6 of the studies in Chronic Urticaria with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868212Phase 3Novartis PharmaceuticalsA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | 2027-02-22 |
| NCT07540910Enanta Pharmaceuticals, IncA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults | 2026-11 |
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
| NCT06931405Blueprint Medicines CorporationStudy of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) | 2026-12-31 |
| NCT06927999ARS Pharmaceuticals, Inc.An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies in Chronic Urticaria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
This study aimed to demonstrate the efficacy of dupilumab in study participants with CSU who remained symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naïve; Study B: omalizumab intolerant or incomplete responders)
Secondary Objectives:
This study aimed to demonstrate the efficacy of dupilumab on urticaria activity composite endpoint and itch or hives, separately, at various timepoints This study aimed to demonstrate the efficacy of dupilumab on angioedema This study aimed to demonstrate the efficacy of dupilumab on urticaria control This study aimed to demonstrate improvement in health-related quality of life and overall disease status and severity This study aimed to evaluate the ability of dupilumab in reducing the proportion of participants who require treatment with oral corticosteroids (OCS) This study aimed to evaluate safety outcome measures This study aimed to evaluate immunogenicity of dupilumab
The duration of study for each participant included 2-4 weeks of screening period, 24 weeks of treatment period and 12 weeks of post treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
UAS7≥16 ISS7≥ 8
Exclusion Criteria:
Participants were excluded from any of the studies if any of the following criteria apply:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who were omalizumab naïve received dupilumab for 24 weeks as follows: * 300 milligrams (mg) SC injection every 2 weeks (q2w) for adults and those adolescents who weighed \>=60 kilograms (kg) at screening starting from Week 2 following a loading dose of 600 mg (2×300 mg injections) on Day 1, * 200 mg SC injection q2w for adolescents who weighed \<60 kg and children (\>=6 to \<12 years of age) who weighed \>=30 kg at screening starting from Week 2 following a loading dose of 400 mg (2×200 mg injections) on Day 1 and * 300 mg SC injection every 4 weeks (q4w) for children (\>=6 to \<12 years of age) who weighed \<30 kg and \>=15 kg at screening starting from Week 4 following a loading dose of 600 mg (2×300 mg injections) on Day 1.
Drug: Dupilumab SAR231893 · Drug: non sedating H1-antihistamine
Participants who were omalizumab naïve received placebo matched to dupilumab as subcutaneous (SC) injection including loading dose from Day 1 up to 24 weeks.
Drug: Placebo · Drug: non sedating H1-antihistamine
Participants who were intolerant or incomplete responders to omalizumab received dupilumab for 24 weeks as follows: * 300 mg SC injection q2w for adults and those adolescents weighing \>=60 kg at screening starting from Week 2 following a loading dose of 600 mg (2×300 mg injections) on Day 1 or * 200 mg SC injection q2w for adolescents weighing \<60 kg at screening starting from Week 2 following a loading dose of 400 mg (2×200 mg injections) on Day 1.
Drug: Dupilumab SAR231893 · Drug: non sedating H1-antihistamine
Participants who were intolerant or incomplete responders to omalizumab received placebo matched to dupilumab as SC injection including loading dose from Day 1 up to 24 weeks.
Drug: Placebo · Drug: non sedating H1-antihistamine
Participants who were omalizumab naïve received dupilumab for 24 weeks as follows: * 300 mg SC injection q2w for adults and those adolescents who weighed \>=60 kg at screening starting from Week 2 following a loading dose of 600 mg (2×300 mg injections) on Day 1, * 200 mg SC injection q2w for adolescents who weighed \<60 kg and children (\>=6 to \<12 years of age) who weighed \>=30 kg at screening starting from Week 2 following a loading dose of 400 mg (2×200 mg injections) on Day 1 and * 300 mg SC injection q4w for children (\>=6 to \<12 years of age) who weighed \<30 kg and \>=15 kg at screening starting from Week 4 following a loading dose of 600 mg (2×300 mg injections) on Day 1.
Drug: Dupilumab SAR231893 · Drug: non sedating H1-antihistamine
Participants who were omalizumab naïve received placebo matched to dupilumab as SC injection including loading dose from Day 1 up to 24 weeks.
Drug: Placebo · Drug: non sedating H1-antihistamine
Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Pharmaceutical form:Tablet Route of administration: oral administration
Change From Baseline in Weekly Itch Severity Score at Week 24
ISS was recorded in e-diary. The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. Least squares (LS) mean is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Weekly Urticaria Activity Score at Week 24
UAS is a validated composite patient-reported outcome (PRO) measure for assessing chronic spontaneous urticaria (CSU) activity. The once daily UAS is the sum of the daily hives severity score (HSS) and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Weekly Hives Severity Score at Week 24
Daily HSS was recorded in e-diary. The HSS7 score is the sum of daily HSS ranging from 0 (none) to 3 (more than 50 hives) recorded by a participant at the same time of each day over 7 days with an overall scale of 0 (no hives) to 21 (severe hives). Higher scores indicate greater intensity of hives. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
Time frame: Baseline (Day 1) and Week 24
Percentage of Responders for Weekly Itch Severity Score Minimally Important Difference (MID) at Week 24
The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. An ISS7 MID response was defined as \>=5 points decrease from baseline after study intervention.
Time frame: Week 24
Percentage of Participants With Weekly Urticaria Activity Score <=6 at Week 24
UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. In evaluating urticaria control using UAS7, an UAS7 score of \<=6 indicated a well-controlled urticaria.
Time frame: Week 24
Percentage of Participants With Weekly Urticaria Activity Score =0 at Week 24
UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. In evaluating urticaria control using UAS7, an UAS7 score of 0 indicated an absence of both itch and hives and a complete resolution of CSU symptoms.
Time frame: Week 24
Change From Baseline in Urticaria Control Test (UCT) at Week 24
The UCT assessed urticaria control based on 4 items (severity of pruritus and wheals urticaria symptoms; frequency of treatment being not sufficient; quality-of-life \[QoL\] impairment; overall urticarial control). Each item was rated on a 5-point Likert-type scale from 0 (no control) to 4 (maximum control). The overall UCT score was the sum of all 4 individual item scores with a range of 0 (no disease control) to 16 (complete disease control). Higher scores indicated greater disease control. LS mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Weekly Itch Severity Score at Week 12
ISS was recorded in e-diary. The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. LS mean is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.
Time frame: Baseline (Day 1) and Week 12
Change From Baseline in Weekly Urticaria Activity Score at Week 12
UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
Time frame: Baseline (Day 1) and Week 12
Percentage of Participants With Weekly Urticaria Activity Score <=6 and =0 at Week 12
UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. In evaluating urticaria control using UAS7, an UAS7 score of \<=6 indicated a well-controlled urticaria and an UAS7 score of 0 indicated an absence of both itch and hives and a complete resolution of CSU symptoms.
Time frame: Week 12
Percentage of Responders for Weekly Itch Severity Score Minimally Important Difference at Week 12
The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. An ISS7 MID response was defined as \>=5 points decrease from baseline after study intervention.
Time frame: Week 12
Change From Baseline in Weekly Hives Severity Score at Week 12
Daily HSS was recorded in e-diary. The HSS7 score is the sum of daily HSS ranging from 0 (none) to 3 (more than 50 hives) recorded by a participant at the same time of each day over 7 days with an overall scale of 0 (no hives) to 21 (severe hives). Higher scores indicate greater intensity of hives. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
Time frame: Baseline (Day 1) and Week 12
Change From Baseline in Urticaria Control Test at Week 12
The UCT assessed urticaria control based on 4 items (severity of pruritus and wheals urticaria symptoms; frequency of treatment being not sufficient; quality-of-life \[QoL\] impairment; overall urticarial control). Each item was rated on a 5-point Likert-type scale from 0 (no control) to 4 (maximum control). The overall UCT score was the sum of all 4 individual item scores with a range of 0 (no disease control) to 16 (complete disease control). Higher scores indicated greater disease control. LS mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.
Time frame: Baseline (Day 1) and Week 12
Change From Baseline in Weekly Itch Severity Score at Weeks 4, 8, 16 and 20
ISS was recorded in e-diary. The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. Mean is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.
Time frame: Baseline (Day 1) and Weeks 4, 8, 16 and 20
Time to First Weekly Itch Severity Score Minimally Important Difference Response During the 24-Week Treatment Period
The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. The MID for ISS7 was a change of 5.0 points. Time to first ISS7 MID response (ISS7 \>=5) was defined as time to reduction from baseline of 5 points or more. Kaplan-Meier estimate is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.
Time frame: Baseline (Day 1) up to Week 24
Change From Baseline in Angioedema Activity Score Over 7 Days (AAS7) at Weeks 12 and 24
The AAS is a diary in which participants document on a daily basis the presence or absence of angioedema during the past 24 hours. If angioedema is present, participants answer 5 additional questions about the time of the day the swelling episode occurred and the severity and impact on daily functioning and appearance this swelling episode has had. Each AAS item is scored between 0 (minimum) and 3 (maximum). The daily AASs range from 0 (no episode) to 15 (severe) points. The AAS7 score is the sum of daily AAS scores reported by a participant at the same time of each day over 7 days, with a range of 0 (no angioedema episodes) to 105 (highest angioedema severity). Higher scores indicate greater angioedema activity. Mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
Time frame: Baseline (Day 1) and Weeks 12 and 24
Percentage of Well-controlled Participants (Urticaria Control Test >=12) at Weeks 12 and 24
The UCT assessed urticaria control based on 4 items (severity of pruritus and wheals urticaria symptoms; frequency of treatment being not sufficient; QoL impairment; overall urticarial control). Each item was rated on a 5-point Likert-type scale from 0 (no control) to 4 (maximum control). The overall UCT score was the sum of all 4 individual item scores with a range of 0 (no disease control) to 16 (complete disease control). Higher scores indicated greater disease control. An UCT score of \>=12 (out of maximum 16) indicated a well-controlled urticaria disease status.
Time frame: Weeks 12 and 24
Change From Baseline in Health-related Quality-of-life (HRQoL) as Measured by Dermatology Life Quality Index (DLQI) in Participants >=16 Years Old at Weeks 12 and 24
The DLQI is an assessment assessing the impact of skin disease on participants' HRQoL over the previous week and contains 10 questions related to symptoms, leisure activities, work/school or holiday time, personal relationships including intimate, the side effects of treatment, and emotional reactions to having a skin disease. The questions (except question 7) were scored on a 4-point Likert scale: 0 (not at all), 1 (a little), 2 (a lot), 3 (very much). Question 7 about work/studying asked whether work/study had been prevented and then (if "No") to what degree the skin condition has been a problem at work/study; the item was again rated on a 3-point Likert scale: 0 (not at all) to 3 (a lot). Total DLQI was calculated by summing the score of each question and ranged from 0 (no impact) to 30 (severe impact). Higher scores indicated poor HRQoL. Mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.
Time frame: Baseline (Day 1) and Weeks 12 and 24
Change From Baseline in Health-related Quality-of-life as Measured by Children's Dermatology Life Quality Index (CDLQI) in Participants >=6 to <16 Years Old at Weeks 12 and 24
The CDLQI is a validated questionnaire designed to measure the impact of skin disease on children's HRQoL. Participants provide responses to 10 questions (symptoms feelings associated with disease, the impact of the disease on leisure, school or holidays, personal relationships, sleep, and side effects of treatment for the skin disease). The instrument has a recall period of 7 days. 9 of the 10 questions are scored on a 4-point Likert scale ranging from 0 (not at all/question unanswered) to 3 (very much). Question 7 has an additional possible response (prevented school) which is assigned a score of 3 (0 \[not at all\] to 3 \[definitely\]). The total CDLQI score is the sum of the score of each question ranging 0 (no impact) to 30 (severe impact). The higher the score, the greater the impact is on the child's HRQoL. Mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.
Time frame: Baseline (Day 1) and Weeks 12 and 24
Patient Global Impression of Change (PGIC) of Chronic Spontaneous Urticaria at Weeks 12 and 24
The PGIC is a 1-item questionnaire that asks the participant to provide the overall self-assessment of change in their CSU on a 7-point scale compared to just before participant started taking the study intervention. Response choices are: 0 (very much better), 1 (moderately better), 2 (a little better), 3 (no change), 4 (a little worse), 5 (moderately worse), 6 (very much worse). Higher score indicate worsening.
Time frame: Weeks 12 and 24
Change From Baseline in Patient Global Impression of Severity (PGIS) of Chronic Spontaneous Urticaria at Weeks 12 and 24
The PGIS is a 1-item questionnaire that asks participants to provide the overall self-assessment of their disease severity on a 4-point scale for the past week. Response choices are: 1 (none), 2 (mild), 3 (moderate), 4 (severe). Higher score indicate more severity. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.
Time frame: Baseline (Day 1) and Weeks 12 and 24
Time to First Oral Corticosteroid (OCS) Use for Chronic Spontaneous Urticaria During the 24-week Treatment Period
Participants receiving OCS as rescue medications for CSU were recorded by the Investigator in e-case report form (eCRF) during the 24-week treatment period. Kaplan-Meier estimate for time to first OCS use is presented.
Time frame: Baseline (Day 1) up to Week 24
Percentage of Participants Receiving Oral Corticosteroid for Chronic Spontaneous Urticaria During the 24-week Treatment Period
Percentage of participants receiving OCS as rescue medications for CSU were recorded by the Investigator in eCRF during the 24-week treatment period.
Time frame: Baseline (Day 1) up to Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.
Time frame: From first dose of study intervention (Day 1) up to end of follow-up, approximately 36 weeks each for Study A, B and C
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Against Dupilumab
Blood samples were collected at specified timepoints and ADA samples were assayed using validated methods. Treatment-emergent ADA response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing. Number of participants with treatment-emergent ADA response is presented.
Time frame: Up to Week 24
This study comprised of 3 randomized studies of similar design: 2 studies were conducted in participants who were omalizumab naïve (Study A \[55 centers in 9 countries\] and Study C \[50 centers in 9 countries\]) and 1 study was conducted in participants who were omalizumab intolerant or incomplete responders (Study B \[61 centers in 11 countries\]).
| Milestone | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Started | 68 | 70 | 54 | 54 | 77 | 74 |
| Completed | 55 | 63 | 47 | 49 | 67 | 66 |
| Not completed | 13 | 7 | 7 | 5 | 10 | 8 |
| Withdrew: Not related to coronavirus disease-2019 (covid-19) | 2 | 1 | 1 | 3 | 2 | 2 |
| Withdrew: Withdrawal by subject | 8 | 4 | 5 | 2 | 8 | 6 |
| Withdrew: Adverse event | 3 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Poor compliance to protocol | 0 | 0 | 1 | 0 | 0 | 0 |
ISS was recorded in e-diary. The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. Least squares (LS) mean is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Change From Baseline in Weekly Itch Severity Score at Week 24 | -6.01 ± 0.94 | -10.24 ± 0.91 | -4.81 ± 1.08 | -7.68 ± 1.10 | -6.10 ± 1.40 | -8.64 ± 1.41 |
UAS is a validated composite patient-reported outcome (PRO) measure for assessing chronic spontaneous urticaria (CSU) activity. The once daily UAS is the sum of the daily hives severity score (HSS) and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Change From Baseline in Weekly Urticaria Activity Score at Week 24 | -12.00 ± 1.81 | -20.53 ± 1.76 | -8.54 ± 2.14 | -14.37 ± 2.16 | -11.21 ± 2.65 | -15.86 ± 2.66 |
Daily HSS was recorded in e-diary. The HSS7 score is the sum of daily HSS ranging from 0 (none) to 3 (more than 50 hives) recorded by a participant at the same time of each day over 7 days with an overall scale of 0 (no hives) to 21 (severe hives). Higher scores indicate greater intensity of hives. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Change From Baseline in Weekly Hives Severity Score at Week 24 | -5.90 ± 0.93 | -10.28 ± 0.91 | -3.63 ± 1.11 | -6.64 ± 1.11 | -5.11 ± 1.31 | -7.27 ± 1.32 |
The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. An ISS7 MID response was defined as \>=5 points decrease from baseline after study intervention.
| percentage of participants | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Percentage of Responders for Weekly Itch Severity Score Minimally Important Difference (MID) at Week 24 | 42.6 | 72.9 | 38.9 | 59.3 | 51.9 | 70.3 |
UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. In evaluating urticaria control using UAS7, an UAS7 score of \<=6 indicated a well-controlled urticaria.
| percentage of participants | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Percentage of Participants With Weekly Urticaria Activity Score <=6 at Week 24 | 23.5 | 45.7 | 18.5 | 24.1 | 23.4 | 40.5 |
UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. In evaluating urticaria control using UAS7, an UAS7 score of 0 indicated an absence of both itch and hives and a complete resolution of CSU symptoms.
| percentage of participants | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Percentage of Participants With Weekly Urticaria Activity Score =0 at Week 24 | 13.2 | 31.4 | 9.3 | 13.0 | 18.2 | 29.7 |
The UCT assessed urticaria control based on 4 items (severity of pruritus and wheals urticaria symptoms; frequency of treatment being not sufficient; quality-of-life \[QoL\] impairment; overall urticarial control). Each item was rated on a 5-point Likert-type scale from 0 (no control) to 4 (maximum control). The overall UCT score was the sum of all 4 individual item scores with a range of 0 (no disease control) to 16 (complete disease control). Higher scores indicated greater disease control. LS mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Change From Baseline in Urticaria Control Test (UCT) at Week 24 | 4.88 ± 0.61 | 7.71 ± 0.59 | 3.38 ± 0.74 | 5.33 ± 0.77 | 4.16 ± 0.94 | 5.09 ± 0.95 |
ISS was recorded in e-diary. The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. LS mean is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Change From Baseline in Weekly Itch Severity Score at Week 12 | -6.01 ± 0.85 | -8.37 ± 0.84 | -4.52 ± 0.95 | -7.37 ± 0.97 | -5.31 ± 1.32 | -7.15 ± 1.32 |
UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Change From Baseline in Weekly Urticaria Activity Score at Week 12 | -11.79 ± 1.64 | -16.81 ± 1.62 | -8.22 ± 1.91 | -13.33 ± 1.94 | -9.51 ± 2.54 | -12.87 ± 2.54 |
UAS is a validated composite PRO measure for assessing CSU activity. The once daily UAS is the sum of the daily HSS and daily ISS recorded in e-diary. Daily HSS assesses number of wheals and range from 0 (none) to 3 (more than 50 hives) whereas daily ISS assesses itch intensity and range from 0 (none) to 3 (intense). The daily UAS scores range from 0 to 6 point/day. Once daily UAS scores are summed over 7-day period to create the UAS7 with an overall scale of 0 (no urticaria) to 42 (severe urticaria). Higher scores indicate greater severity of urticaria symptoms. In evaluating urticaria control using UAS7, an UAS7 score of \<=6 indicated a well-controlled urticaria and an UAS7 score of 0 indicated an absence of both itch and hives and a complete resolution of CSU symptoms.
| percentage of participants | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| UAS7 <=6 | 17.6 | 34.3 | 9.3 | 24.1 | 16.9 | 31.1 |
| UAS7=0 | 8.8 | 15.7 | 1.9 | 13.0 | 11.7 | 17.6 |
The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. An ISS7 MID response was defined as \>=5 points decrease from baseline after study intervention.
| percentage of participants | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Percentage of Responders for Weekly Itch Severity Score Minimally Important Difference at Week 12 | 52.9 | 70.0 | 46.3 | 64.8 | 51.9 | 58.1 |
Daily HSS was recorded in e-diary. The HSS7 score is the sum of daily HSS ranging from 0 (none) to 3 (more than 50 hives) recorded by a participant at the same time of each day over 7 days with an overall scale of 0 (no hives) to 21 (severe hives). Higher scores indicate greater intensity of hives. LS mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Change From Baseline in Weekly Hives Severity Score at Week 12 | -5.69 ± 0.83 | -8.39 ± 0.83 | -3.71 ± 1.01 | -5.97 ± 1.02 | -4.22 ± 1.28 | -5.75 ± 1.28 |
The UCT assessed urticaria control based on 4 items (severity of pruritus and wheals urticaria symptoms; frequency of treatment being not sufficient; quality-of-life \[QoL\] impairment; overall urticarial control). Each item was rated on a 5-point Likert-type scale from 0 (no control) to 4 (maximum control). The overall UCT score was the sum of all 4 individual item scores with a range of 0 (no disease control) to 16 (complete disease control). Higher scores indicated greater disease control. LS mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Change From Baseline in Urticaria Control Test at Week 12 | 4.62 ± 0.57 | 6.48 ± 0.57 | 3.11 ± 0.65 | 5.48 ± 0.67 | 3.26 ± 0.88 | 4.61 ± 0.89 |
ISS was recorded in e-diary. The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. Mean is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Week 4 | -3.30 ± 6.54 | -4.96 ± 5.49 | -4.12 ± 6.28 | -5.51 ± 5.64 | -3.78 ± 4.73 | -5.26 ± 5.16 |
| Week 8 | -4.98 ± 7.49 | -6.99 ± 6.78 | -4.27 ± 5.92 | -7.25 ± 6.29 | -4.92 ± 5.67 | -7.83 ± 6.02 |
| Week 16 | -5.61 ± 7.45 | -9.43 ± 6.86 | -4.52 ± 6.68 | -8.05 ± 7.43 | -6.22 ± 5.78 | -8.24 ± 7.37 |
| Week 20 | -6.40 ± 7.82 | -10.04 ± 7.22 | -5.35 ± 7.17 | -7.54 ± 7.94 | -6.64 ± 6.43 | -9.27 ± 6.58 |
The ISS represents severity of itch on a scale ranging from 0 (none) to 3 (intense). The ISS7 score was the sum of daily ISS scores recorded by a participant at the same time each day over 7 days with an overall scale of 0 (no impact) to 21 (severe impact). Higher scores indicated greater intensity of itch. The MID for ISS7 was a change of 5.0 points. Time to first ISS7 MID response (ISS7 \>=5) was defined as time to reduction from baseline of 5 points or more. Kaplan-Meier estimate is presented. Baseline was defined as the sum of daily scores obtained for 7 days prior to randomization.
| weeks | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Time to First Weekly Itch Severity Score Minimally Important Difference Response During the 24-Week Treatment Period | 4.0 (2.0 to 8.0) | 3.0 (2.0 to 5.0) | 4.0 (2.0 to 7.0) | 3.0 (2.0 to 4.0) | 5.0 (3.0 to 7.0) | 3.5 (3.0 to 5.0) |
The AAS is a diary in which participants document on a daily basis the presence or absence of angioedema during the past 24 hours. If angioedema is present, participants answer 5 additional questions about the time of the day the swelling episode occurred and the severity and impact on daily functioning and appearance this swelling episode has had. Each AAS item is scored between 0 (minimum) and 3 (maximum). The daily AASs range from 0 (no episode) to 15 (severe) points. The AAS7 score is the sum of daily AAS scores reported by a participant at the same time of each day over 7 days, with a range of 0 (no angioedema episodes) to 105 (highest angioedema severity). Higher scores indicate greater angioedema activity. Mean is presented. Baseline was defined as the sum of the daily scores for the 7 days prior to the day of randomization.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Week 12 | -23.46 ± 21.76 | -19.14 ± 18.89 | -16.74 ± 21.74 | -19.41 ± 34.44 | -32.14 ± 32.15 | -34.33 ± 36.19 |
| Week 24 | -23.56 ± 23.04 | -18.76 ± 22.85 | -15.83 ± 25.73 | -13.95 ± 37.22 | -31.00 ± 36.38 | -36.28 ± 27.61 |
The UCT assessed urticaria control based on 4 items (severity of pruritus and wheals urticaria symptoms; frequency of treatment being not sufficient; QoL impairment; overall urticarial control). Each item was rated on a 5-point Likert-type scale from 0 (no control) to 4 (maximum control). The overall UCT score was the sum of all 4 individual item scores with a range of 0 (no disease control) to 16 (complete disease control). Higher scores indicated greater disease control. An UCT score of \>=12 (out of maximum 16) indicated a well-controlled urticaria disease status.
| percentage of participants | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Week 12 | 27.9 | 44.3 | 18.5 | 51.9 | 22.1 | 37.8 |
| Week 24 | 30.9 | 48.6 | 20.4 | 44.4 | 39.0 | 50.0 |
The DLQI is an assessment assessing the impact of skin disease on participants' HRQoL over the previous week and contains 10 questions related to symptoms, leisure activities, work/school or holiday time, personal relationships including intimate, the side effects of treatment, and emotional reactions to having a skin disease. The questions (except question 7) were scored on a 4-point Likert scale: 0 (not at all), 1 (a little), 2 (a lot), 3 (very much). Question 7 about work/studying asked whether work/study had been prevented and then (if "No") to what degree the skin condition has been a problem at work/study; the item was again rated on a 3-point Likert scale: 0 (not at all) to 3 (a lot). Total DLQI was calculated by summing the score of each question and ranged from 0 (no impact) to 30 (severe impact). Higher scores indicated poor HRQoL. Mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Week 12 | -7.55 ± 7.47 | -8.55 ± 6.27 | -4.53 ± 6.28 | -6.77 ± 6.92 | -5.01 ± 6.25 | -6.61 ± 7.04 |
| Week 24 | -7.56 ± 8.13 | -9.50 ± 5.92 | -4.96 ± 6.87 | -6.91 ± 7.51 | -6.81 ± 6.54 | -8.09 ± 7.66 |
The CDLQI is a validated questionnaire designed to measure the impact of skin disease on children's HRQoL. Participants provide responses to 10 questions (symptoms feelings associated with disease, the impact of the disease on leisure, school or holidays, personal relationships, sleep, and side effects of treatment for the skin disease). The instrument has a recall period of 7 days. 9 of the 10 questions are scored on a 4-point Likert scale ranging from 0 (not at all/question unanswered) to 3 (very much). Question 7 has an additional possible response (prevented school) which is assigned a score of 3 (0 \[not at all\] to 3 \[definitely\]). The total CDLQI score is the sum of the score of each question ranging 0 (no impact) to 30 (severe impact). The higher the score, the greater the impact is on the child's HRQoL. Mean is presented. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Week 12 | -5.00 ± NA | -8.00 ± 5.66 | — | -7 ± NA | -4.60 ± 10.04 | -9.00 ± 2.83 |
| Week 24 | — | -12.50 ± 12.02 | — | -7 ± NA | -5.60 ± 7.83 | -4.50 ± 7.78 |
The PGIC is a 1-item questionnaire that asks the participant to provide the overall self-assessment of change in their CSU on a 7-point scale compared to just before participant started taking the study intervention. Response choices are: 0 (very much better), 1 (moderately better), 2 (a little better), 3 (no change), 4 (a little worse), 5 (moderately worse), 6 (very much worse). Higher score indicate worsening.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Week 12 | 1.68 ± 1.43 | 1.10 ± 1.24 | 2.06 ± 1.29 | 1.62 ± 1.46 | 1.59 ± 1.23 | 1.27 ± 1.44 |
| Week 24 | 1.70 ± 1.50 | 1.04 ± 1.51 | 1.90 ± 1.64 | 1.44 ± 1.55 | 1.18 ± 1.36 | 1.01 ± 1.48 |
The PGIS is a 1-item questionnaire that asks participants to provide the overall self-assessment of their disease severity on a 4-point scale for the past week. Response choices are: 1 (none), 2 (mild), 3 (moderate), 4 (severe). Higher score indicate more severity. Baseline was defined as the last available value up to randomization date and prior to the first dose of study intervention.
| score on a scale | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Week 12 | -0.89 ± 0.98 | -1.23 ± 0.93 | -0.46 ± 0.93 | -1.15 ± 1.04 | -0.82 ± 0.98 | -0.95 ± 0.97 |
| Week 24 | -0.97 ± 1.18 | -1.44 ± 0.92 | -0.54 ± 1.16 | -0.96 ± 1.05 | -1.03 ± 1.09 | -1.33 ± 1.05 |
Participants receiving OCS as rescue medications for CSU were recorded by the Investigator in e-case report form (eCRF) during the 24-week treatment period. Kaplan-Meier estimate for time to first OCS use is presented.
| weeks | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Time to First Oral Corticosteroid (OCS) Use for Chronic Spontaneous Urticaria During the 24-week Treatment Period | 0.110 (0.048 to 0.200) | 0.087 (0.035 to 0.168) | 0.158 (0.074 to 0.271) | 0.116 (0.047 to 0.220) | 0.067 (0.025 to 0.138) | 0.014 (0.001 to 0.068) |
Percentage of participants receiving OCS as rescue medications for CSU were recorded by the Investigator in eCRF during the 24-week treatment period.
| percentage of participants | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Percentage of Participants Receiving Oral Corticosteroid for Chronic Spontaneous Urticaria During the 24-week Treatment Period | 10.3 | 8.6 | 14.8 | 11.1 | 6.5 | 1.4 |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.
| Participants | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| TEAEs | 40 | 38 | 29 | 33 | 41 | 40 |
| TESAEs | 5 | 2 | 2 | 3 | 1 | 5 |
Blood samples were collected at specified timepoints and ADA samples were assayed using validated methods. Treatment-emergent ADA response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing. Number of participants with treatment-emergent ADA response is presented.
| Participants | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Against Dupilumab | 1 | 9 | 2 | 10 | 0 | 1 |
Collected over From first dose of study intervention (Day 1) up to end of follow-up, approximately 36 weeks each for Study A, B and C. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Study A: Placebo | 1/68 (1.5%) | 5/68 (7.4%) | 19/68 (27.9%) |
| Study A: Dupilumab | 0/70 (0%) | 2/70 (2.9%) | 12/70 (17.1%) |
| Study B: Placebo | 0/54 (0%) | 2/54 (3.7%) | 15/54 (27.8%) |
| Study B: Dupilumab | 0/54 (0%) | 3/54 (5.6%) | 17/54 (31.5%) |
| Study C: Placebo | 0/77 (0%) | 1/77 (1.3%) | 15/77 (19.5%) |
| Study C: Dupilumab | 0/74 (0%) | 5/74 (6.8%) | 20/74 (27%) |
| Event | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Intestinal ObstructionGastrointestinal disorders | 0/68 | 0/70 | 0/54 | 1/54 | 0/77 | 0/74 |
| Chronic Spontaneous UrticariaSkin and subcutaneous tissue disorders | 0/68 | 0/70 | 0/54 | 1/54 | 0/77 | 0/74 |
| Idiopathic AngioedemaSkin and subcutaneous tissue disorders | 0/68 | 0/70 | 0/54 | 1/54 | 0/77 | 0/74 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/68 | 0/70 | 1/54 | 0/54 | 0/77 | 0/74 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 0/68 | 0/70 | 1/54 | 0/54 | 0/77 | 0/74 |
| Covid-19 PneumoniaInfections and infestations | 1/68 | 0/70 | 0/54 | 0/54 | 0/77 | 0/74 |
| Completed SuicidePsychiatric disorders | 1/68 | 0/70 | 0/54 | 0/54 | 0/77 | 0/74 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/68 | 0/70 | 0/54 | 0/54 | 0/77 | 0/74 |
| Abdominal Pain UpperGastrointestinal disorders | 1/68 | 0/70 | 0/54 | 0/54 | 0/77 | 0/74 |
| NauseaGastrointestinal disorders | 1/68 | 0/70 | 0/54 | 0/54 | 0/77 | 0/74 |
| Event | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab |
|---|---|---|---|---|---|---|
| Chronic Spontaneous UrticariaSkin and subcutaneous tissue disorders | 6/68 | 3/70 | 3/54 | 6/54 | 3/77 | 2/74 |
| Covid-19Infections and infestations | 2/68 | 1/70 | 4/54 | 5/54 | 4/77 | 6/74 |
| NasopharyngitisInfections and infestations | 3/68 | 1/70 | 4/54 | 1/54 | 6/77 | 4/74 |
| Accidental OverdoseInjury, poisoning and procedural complications | 0/68 | 1/70 | 2/54 | 3/54 | 2/77 | 5/74 |
| AngioedemaSkin and subcutaneous tissue disorders | 4/68 | 1/70 | 0/54 | 2/54 | 1/77 | 3/74 |
| Injection Site ErythemaGeneral disorders | 4/68 | 3/70 | 3/54 | 0/54 | 0/77 | 4/74 |
| Injection Site ReactionGeneral disorders | 2/68 | 4/70 | 1/54 | 1/54 | 1/77 | 3/74 |
| HypertensionVascular disorders | 0/68 | 0/70 | 1/54 | 3/54 | 0/77 | 0/74 |
Analysis was performed on randomized population.
| Age, Continuous(years) | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab | Total |
|---|---|---|---|---|---|---|---|
| Mean | 41.9 ± 14.8 | 40.7 ± 16.2 | 46.8 ± 16.3 | 48.6 ± 15.6 | 44.0 ± 16.7 | 45.6 ± 17.1 | 44.4 ± 16.3 |
| Sex: Female, Male(Participants) | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab | Total |
|---|---|---|---|---|---|---|---|
| Female | 50 | 41 | 41 | 37 | 59 | 47 | 275 |
| Male | 18 | 29 | 13 | 17 | 18 | 27 | 122 |
| Race (NIH/OMB)(Participants) | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| Asian | 16 | 19 | 11 | 6 | 29 | 33 | 114 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 2 | 1 | 2 | 3 | 2 | 0 | 10 |
| White | 48 | 47 | 41 | 43 | 38 | 32 | 249 |
| More than one race | 1 | 1 | 0 | 0 | 2 | 1 | 5 |
| Unknown or Not Reported | 1 | 1 | 0 | 1 | 6 | 7 | 16 |
| Weekly Itch-Severity (ISS7) Score(score on a scale) | Study A: Placebo | Study A: Dupilumab | Study B: Placebo | Study B: Dupilumab | Study C: Placebo | Study C: Dupilumab | Total |
|---|---|---|---|---|---|---|---|
| Mean | 15.7 ± 4.1 | 16.1 ± 4.0 | 16.2 ± 3.8 | 15.9 ± 4.0 | 15.0 ± 3.9 | 15.3 ± 3.6 | 15.7 ± 3.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Dec 2019 to primary completion in Aug 2024, 55 months.
Results were first posted in Aug 2025, 1 year after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's 55 months is above that.
Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab